SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Revolution Medicines is trending as investors digest strong topline results from its Phase 3 RASolute 302 clinical trial, triggering significant price appreciation and active discussion regarding the company's future as a potential buyout target. Community sentiment remains highly bullish, with many highlighting the stock's robust cash position and the transformative potential of its daraxonrasib treatment for pancreatic cancer.

The Goldman Sachs Group, Inc. engages in the provision of financial services. It operates through the following business segments: Global Banking and Markets, Asset and Wealth Management, and Platform Solutions. The Global Banking and Markets segment includes investment banking, global investments, and equity and debt investments. The Asset and Wealth Management segment relates to the direct-to-consumer banking business which includes lending, deposit-taking, and investing. The Platform Solutions segment includes consumer platforms such as partnerships offering credit cards and point-of-sale financing, and transaction banking. The company was founded by Marcus Goldman in 1869 and is headquartered in New York, NY.

Goldman Sachs Group, Inc.

Goldman Sachs is trending due to the resignation of its top lawyer amid revelations of ongoing ties to Jeffrey Epstein, triggering a sharp decline in share price. Investors are also closely monitoring the bank's exposure to volatile credit markets and broader concerns regarding institutional stability during a period of geopolitical uncertainty.

Maulcoin

Maulcoin is capturing attention as a community-driven meme project that is consistently trending on social platforms without an official chart, fueling intense community speculation about an upcoming breakout. Holders are actively discussing milestone targets for market capitalization and expressing strong commitment to the project's long-term growth and cultural branding.

Aeluma, Inc. engages in developing semiconductors for sensing, communication, and computing applications. The firm is also involved in manufacturing devices using compound semiconductor materials on large-diameter substrates that are commonly used to manufacture mass market microelectronics. The company was founded by Jonathan Klamkin and Lee McCarthy on February 28, 2019 and is headquartered in Goleta, CA.

Aeluma Inc

Aeluma is trending as investors weigh its potential for massive growth in silicon photonics against the execution risks associated with its transition from early-stage government contracts to commercial-scale manufacturing. Community sentiment is sharply divided between those bullish on its proprietary 300mm wafer technology as a high-reward play and those skeptical of its current revenue levels and recurring share offerings.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing significant market interest driven by a combination of high trading volume, a short squeeze, and momentum following its expansion and integration with the USD1-denominated ecosystem. While some community members are actively debating the token's long-term utility and governance, others are focused on its rapid price action and speculative potential as a trending Web3 entertainment protocol.

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ and GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Ideaya Biosciences Inc

Ideaya Biosciences is surging following positive Phase 2/3 trial results for its metastatic uveal melanoma treatment, which significantly improved progression-free survival compared to standard therapies. Investors and the community are actively debating the potential for an accelerated FDA filing, while also closely watching for future pipeline updates and high institutional interest.

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.

Spyre Therapeutics Inc.

Aeglea BioTherapeutics Inc

Spyre Therapeutics is seeing significant investor interest following positive clinical data for its SPY001 program, with the community actively discussing the company's multi-pathway platform approach and its potential to disrupt the IBD market. While some investors are focused on the long-term potential of its upcoming pipeline milestones, others remain cautious regarding the risks typically associated with clinical-stage biotechnology companies.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently trading in a volatile spotlight following a combination of a high-profile endorsement from Donald Trump and intense short-selling pressure from investors like Michael Burry. The community remains deeply divided, with bulls pointing to the company's critical role in military AI and defense contracts, while bears raise significant concerns regarding its current valuation and rising competition from alternative AI models.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

The VanEck Semiconductor ETF is experiencing intense volatility and heightened scrutiny as traders debate whether current valuation levels represent a sustainable AI-driven growth cycle or an overheated bubble. The community is actively tracking a sharp divergence between high-flying hardware momentum and a struggling software sector, while aggressive options activity and short-dated put sweeps suggest that institutional players are bracing for significant downside risks.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.

Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals is facing intense community debate as investors weigh concerns over potential dilution and future stock splits against optimism surrounding the commercial traction and insurance coverage expansion of their lead product, Tonmya. While some shareholders are selling amid downward price pressure and a history of capital raises, others are aggressively buying the dip, citing strong long-term pipeline fundamentals and recent insider share purchases as evidence of an impending turnaround.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ukraine Ditches NATO Membership Bid: A Defense ETF Buying Opportunity?

Ukraine's signal to drop its NATO bid hits European defense shares, but the pullback may favor diversified defense ETFs like XAR. 

<ul class="summary-bullets"><li>The Düsseldorf-based company reported a backlog of 64 billion euros at the end of the third quarter of 2025, a fivefold increase from its order book of 12.9 billion euros at the end of 2020.</li><li>U.S. President Donald Trump has also pushed the EU countries to raise their defense spending goals to cut reliance on Washington, D.C</li><li>Recent drone sightings in several NATO member states have also raised concerns, underscoring the need for robust air defense systems.</li></ul>Rheinmetall’s stock has jumped around 164% this year in Europe, while its American Depositary Receipts have fared even better by more than tripling, keeping the German defense firm’s shares on track for their largest-ever annual gains.Last month, the company surprised analysts by projecting 50 billion euros ($58.7 billion) in annual sales in 2030, compared with the 9.8 billion euros it logged last year. Its ambitious projections came amid renewed interest in defense spending in Europe and a lack of progress in Ukraine peace efforts.<figure class="image"><img style="aspect-ratio:2400/1240;" src="https://news.stocktwits-cdn.com/koyfin_20251215_044634975_png_a4b0094e22.webp" alt="koyfin_20251215_044634975.png" width="2400" height="1240"><figcaption>YTD performance of Rheinmetall&nbsp;</figcaption></figure><h2 class="st-heading-2">Soaring Backlog</h2>The Düsseldorf-based company reported a backlog of 64 billion euros at the end of the third quarter of 2025, a fivefold increase from its order book of 12.9 billion euros at the end of 2020. The company stated that the most significant share of its 2030 sales will come from its weapons and ammunition division and its vehicle systems segment, driven by demand in Germany.The meteoric rise, despite the absence of any major U.S. orders, was driven by increased defense spending in Europe following the Russian invasion of Ukraine. U.S. President Donald Trump has also pushed the EU countries to raise their defense spending goals to cut reliance on Washington, D.C. The European Union unveiled a new “ReArm Europe” strategy earlier this year, earmarking 800 billion euros to boost European defense capabilities, with Rheinmetall expected to be a key beneficiary of the spending increase.Recent drone sightings in several NATO member states have also raised concerns, underscoring the need for robust air defense systems. Last week, the German firm won a significant order from the Netherlands for its Skyranger 30 air defense systems, valued at triple-digit million euros.<h2 class="st-heading-2">What Are Analysts Saying?</h2>As reported by investing.com, Bernstein reaffirmed its fundamental stance on the stock last week but raised its price target to 2,050 euros from 1,980 euros, citing an improved risk-reward trade-off amid a 20% decline in share price since September.The analysts noted that, following the slump, the stock trades in line with European peers in defense in 2028 but at a discount in 2030, despite higher growth/margin expectations for this stock than its sector.<h2 class="st-heading-2">What Are Stocktwits Users Thinking?</h2>Retail sentiment about the U.S. ADR of <a href="https://stocktwits.com/symbol/RNMBY">Rheinmetall</a> was in the ‘neutral’ territory at the time of writing.<figure class="image"><img style="aspect-ratio:720/96;" src="https://news.stocktwits-cdn.com/RNMBY_D_Ec_15_JPG_b1c7e69b82.webp" alt="RNMBY’s Sentiment Meter and Message Volume as of 04:36 a.m. ET on Dec. 15, 2025 | Source: Stocktwits" width="720" height="96"><figcaption>RNMBY’s Sentiment Meter and Message Volume as of 04:36 a.m. ET on Dec. 15, 2025 | Source: Stocktwits</figcaption></figure>Rheinmetall stock got a further boost this year after it replaced Kering SA in the Euro Stoxx 50 benchmark.Also See: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-ethereum-see-outflows-while-xrp-etfs-log-1-billion-in-30-day-inflow-run/cLeEDjbRE8F">Bitcoin, Ethereum Funds See Outflows While XRP ETFs Log Nearly $1 Billion In Unbroken 30-Day Inflow Streak Since Debut</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Various Rheinmetall 155mm artillery ammunition is displayed during the Security Equipment International (DSEI) at London Excel on September 09, 2025 in London, England.

Rheinmetall Reloaded: Europe’s Defense Boom Turns Into A Historic Stock Run

Last month, the company surprised analysts by projecting 50 billion euros in annual sales in 2030, compared with the 9.8 billion euros it logged last year.

Equity

German defense firm Rheinmetall stock (RNMBY) saw a surge in retail interest on Wednesday after U.S. President Donald Trump stated that Ukraine can reclaim all its territories, marking a reversal of his earlier stance."Putin and Russia are in BIG Economic trouble, and this is the time for Ukraine to act," Trump wrote on Truth Social on Tuesday, after meeting his European counterpart Volodomyr Zelenskyy on the sidelines of the United Nations General Assembly."After seeing the Economic trouble (the war) is causing Russia, I think Ukraine, with the support of the European Union, is in a position to fight and WIN all of Ukraine back in its original form," he said.His remarks marked a rapid shift since an infamous verbal clash with Zelenskyy at the Oval Office earlier this year. Trump had earlier urged Ukraine to cede some of its territories to bring an end to the over three-year-old conflict.According to a Reuters News report, Zelenskyy later told Fox News that he believed the positions of the Ukrainian and U.S. teams were "closer than any time before," and that he thought Trump's position had changed.While German defense firm <a href="https://stocktwits.com/symbol/RNMBY">Rheinmetall</a>’s U.S. shares were down in premarket trading, its European shares were up 1.4%. Retail sentiment on Stocktwits moved to ‘neutral’ from ‘bearish’ a day ago.<figure class="image"><img style="aspect-ratio:708/85;" src="https://news.stocktwits-cdn.com/Rheinmetal_JPG_5cc661f658.webp" alt="RNMBY’s Sentiment Meter and Message Volume as of 04:51 a.m. ET on Sept. 24, 2025 | Source: Stocktwits" width="708" height="85"><figcaption>RNMBY’s Sentiment Meter and Message Volume as of 04:51 a.m. ET on Sept. 24, 2025 | Source: Stocktwits</figcaption></figure>Russia currently holds about 20% of Ukrainian territory, and a complete withdrawal will require Russia also to forgo claims on the Crimean peninsula, which it annexed controversially in 2014. According to an AFP report, the Kremlin replied that there was “no alternative” for Russia than to continue its offensive on Ukraine that it launched in 2022.“[A] good opportunity to make a lot of money,” one trader said.<stembedurl>https://stocktwits.com/DigFlier/message/629747163</stembedurl>Rheinmetall AG's stock, which trades over-the-counter, has more than tripled in value this year.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/energy-fuels-stock-s-retail-chatter-heats-up-as-congressional-visit-raises-speculation-of-us-deal/chDKwlZR3dM">Energy Fuels Stock’s Retail Chatter Heats Up As Congressional Visit Raises Speculation Of US Deal</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rheinmetall Stock Ignites Retail Buzz After Trump’s About-Face On Ukraine Policy

Trump had earlier urged Ukraine to cede some of its territories to bring an end to the over three-year-old conflict.

Six ways to invest in Europe right now

Investing.com -- European stocks are drawing attention again as defense spending rises, governments loosen purse strings, and interest rate pressures ease. UBS highlights six themes where investors can find value, despite an overall neutral stance on the region.

Rheinmetall AG Unsponsored ADR (RNMBY) Is a Great Choice for 'Trend' Investors, Here's Why  

Rheinmetall AG Unsponsored ADR (RNMBY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

European oil and defense stocks slip amid Israel-Iran ceasefire

Investing.com - Shares in European energy and defense stocks fell on Tuesday following U.S. President Donald Trump’s announcement of a ceasefire between Israel and Iran.

Here's Why Momentum in Rheinmetall AG Unsponsored ADR (RNMBY) Should Keep going

European Commodities: German Stocks Approach Double-Top Resistance

The V-shaped recovery in Germany's benchmark index could be at risk as stiff resistance looms.

Rheinmetall shares surge after preliminary first-quarter sales beat estimates

Investing.com -  Rheinmetall  (ETR:RHMG) has reported a jump in preliminary first-quarter sales that topped expectations, as Europe’s largest maker of ammunition was boosted by solid demand at its defense segment.

Moody's upgrades Rheinmetall to Baa1 with stable outlook

Investing.com -- Moody's Ratings has upgraded  Rheinmetall  AG's (ETR:RHMG) long-term issuer rating to Baa1 from Baa2, while affirming its P-2 short-term ratings with a stable outlook. This upgrade reflects the German defense contractor's robust operating performance since April 2022, demonstrated by nearly doubled revenue and a record €55 billion order backlog.

Rheinmetall AG is a holding company, which engages in the provision of development and sale of components, systems, and services for the security and civil industries. It operates through the following segments: Vehicle Systems, Weapon and Ammunition, Electronic Solutions, Sensors and Actuators, Materials and Trade, and Others. The Vehicle Systems segment offers a diverse portfolio of vehicles, including combat, support, logistics, and special vehicles. The Weapon and Ammunition segment includes products and solutions for threat-appropriate, firepower as well as comprehensive protection. The Electronic Solutions segment is involved in the chain of effects in the system network, from sensors and the networking of platforms and soldiers to the automated connection of effectors, as well as solutions for protection in cyberspace. The Sensors and Actuators consists of a product portfolio with exhaust gas recirculation systems, throttle valves, control dampers, and exhaust flaps for electromotors, solenoid valves, actuators and valve train systems, oil, water, and vacuum pumps for passenger cars, commercial vehicles, and light and heavy-duty off-road applications, as well as industrial solutions. The Materials and Trade segment focuses on the development of system components for the basic motor. The company was founded by Heinrich Ehrhardt on April 13, 1889 and is headquartered in Duesseldorf, Germany.

RNMBY
Rheinmetall AG - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RNMBY News

RNMBYRheinmetall AG - ADR